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Background
Pulmonary disease may be developed in children with
juvenile systemic sclerosis (J-SSc) [1] and mixed connec-
tive tissue disease. Limited information is available con-
cerning juvenile mixed connective tissue disease (J-
MCTD).
Materials and methods
To evaluate the prognostic value of pulmonary disease in
children with J-SSc and J-MCTD we reviewed the chil-
dren's records with a diagnosis of J-SSc and J-MCTD since
1989 and a minimum follow-up of 5 years.
Results
Six (5 female, 1 male) children with J-SSc or J-MCTD were
studied. The age at the disease onset ranged from 2–13 yrs.
The follow-up duration was 6–18 yrs (mean 10 yrs). Four
children had J-SSc and two had J-MCTD. Three children
developed interstitial lung involvement proven by HRCT
or chest x-ray. Pulmonary arterial hypertension (PAH)
occurred in three children, two with J-SSc and one with J-
MCTD. One of the two children with J-SSc, x-ray findings
of lung involvement and PAH died. In this child the
involvement of the respiratory system occurred within the
first year of the disease. In the two other children with J-
SSc or J-MCTD, interstitial lung involvement and PAH
subsided after a course of aggressive therapy with corticos-
teroid, cyclophosphamide and bosentan. Bone marrow
transplantation was performed in one child with J-SSc and
PAH.
Conclusion
Severe pulmonary disease may implicate the clinical
course of J-SSc and J-MCTD. Pulmonary arterial hyperten-
sion indicates very poor prognosis. HRCT may identify
those children with interstitial lung involvement who are
candidates for aggressive therapy.
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